Andrew A. Komjathy

Andrew Komjathy is an accomplished commercial leader with extensive experience in the biopharmaceutical industry. Currently serving as Chief Commercial Officer at Astria Therapeutics, Inc. since September 2019, Andrew is responsible for setting the commercial vision and strategy for the company’s pipeline, focusing on patient access to rare therapies. Previously, Andrew held the position of VP Commercial Sales at Alkermes, managing a large team dedicated to addiction recovery and CNS. Andrew also served as Vice President of Sales for the US Multiple Sclerosis Franchise at Genzyme, leading the launch of Aubagio. Prior roles include VP of Commercial Operations at Shire HGT, where pre-launch strategies for Replagal were developed, and various positions at Shire Human Genetic Therapies, including global responsibility for key products. Andrew began the career at Allergan as District Manager and further gained experience at Biogen Idec in leadership roles for product launches and management across North America. Andrew holds an MBA in International Finance from NYU Stern School of Business and a BSBA in Management from Bucknell University.